Join leaders, experts and scientists to accelerate COVID-19 drug discovery and development
The programme brings together international pharmaceutical organisations, biotech companies and academic institutions specialising in discovery, diagnosis and clinical development.
It includes over 20 cutting-edge presentations and workshops, over 8 hours of valuable networking sessions, over our digital networking platform.
We are looking to hear speakers working in discovery, diagnosis and clinical development related to COVID-19. Please contact Cerlin Roberts with your proposals.
Online Booking for Virtual Symposium: COVID-19 Drug Discovery & Development is now open. Secure your place today!
Stay up to date with the latest news and developments in our LinkedIn group dedicated to news and research relating to COVID-19 Drug Discovery & Development.
Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions working on COVID-19 Discovery and Development.
A look at the new modalities in discovery of therapeutic peptides, monoclonal antibodies and broad-spectrum antivirals
Hear the latest updates on the integration of screening and assay development approaches
Gain insights into modelling and computing techniques, AI and Bioinformatics tools
Explore successful development of point-of-care diagnostic tests, diagnostics tools and technologies for patient monitoring and treatment
Learn from Clinical Trial Development Updates for COVID-19
Engage with peers and selected leading providers in an interactive digital networking environment
Discovery Programs for COVID-19 Targets
The Symposium brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.
Stanford University School of Medicine
Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual experiences.